Treatment guidelines
Recommendations for RA management with conventional or biologic DMARDs (2019 update)4
Early RA
Guidelines for RA with disease duration <6 months (2015)3
Established RA
Guidelines for RA with disease duration ≥6 months (2015)3
High-risk patients
Guidelines for established RA and moderate or high disease activity and CHF, hepatitis B or C, past history of malignancy, or serious infection(s)3
Vaccine recommendations
Recommendations for vaccination in adult patients with AIIRDs5
Recommendations for the use of vaccines in patients with RA starting or receiving DMARDs or biologics3
RA management during the COVID-19 pandemic
COVID-19 recommendations
Provisional recommendations for the management of RMDs in the context of SARS-CoV-27
COVID-19 guidance
Recommendations for the management of rheumatic disease in adults during the COVID-19 pandemic6
COVID-19 vaccine for patients with RMD
COVID-19 vaccine viewpoints
Responses to FAQs by patients with RMDs regarding the use of immunosuppressants and SARS-CoV-2 vaccinations9
COVID-19 vaccine guidance
Clinical guidance summary for SARS-CoV-2 vaccination in patients with RMDs8
AIIRD, autoimmune inflammatory rheumatic disease; ACR, American College of Rheumatology; CHF, congestive heart failure; DMARD, disease-modifying antirheumatic drug; EULAR, European Alliance of Associations for Rheumatology; FAQ, frequently asked questions; RA, rheumatoid arthritis; RMD, rheumatic and musculoskeletal disease; SARS-CoV-2, severe acute respiratory syndrome-related coronavirus 2.
REFERENCES
1. About EULAR. European Alliance of Associations for Rheumatology. Accessed March 19, 2021. https://www.eular.org/eular_about.cfm. 2. About us. American College of Rheumatology. Accessed March 19, 2021. https://www.rheumatology.org/About-Us 3. Singh JA, Saag KG, Bridges SL Jr, et al. Arthritis Care Res (Hoboken). 2016;68(1):1-25. 4. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. Ann Rheum Dis. 2020;79(6):685-699. 5. Furer V, Rondaan C, Heijstek MW, et al. Ann Rheum Dis. 2020;79(1):39-52. 6. Mikuls TR, Johnson SR, Fraenkel L, et al. Arthritis Rheumatol. 2021;73(2):e1-e12. 7. Landewé RB, Machado PM, Kroon F, et al. Ann Rheum Dis. 2020;79(7):851-858. 8. American College of Rheumatology COVID-19 Vaccine Clinical Guidance Task Force. COVID-19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases. Updated March 4, 2021. Accessed March 22, 2021. https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf 9. Bijlsma JWJ. Ann Rheum Dis. 2021;80:411-412.
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos
NV.
© Galapagos Biopharma Sweden AB.
Vasagatan 7, 101 23 Stockholm, Sweden, VAT: SE559311454801. All rights reserved.
SE-RA-JY-202203-00001
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos
NV.
© Galapagos Biopharma Sweden AB.
Vasagatan 7, 101 23 Stockholm, Sweden, VAT: SE559311454801. All rights reserved.
SE-RA-JY-202203-00001
© Copyright 2021 Galapagos NV
You are about to leave this website and will be redirected to an external website. We are not responsible of that external website’s content. By continuing, you confirm that you have taken note of this.
